CytRx reports upbeat interim study results
May 04, 2015 at 13:59 PM EDT
CytRx
Corp. (Nasdaq: CYTR) reported upbeat interim results from two ongoing
Phase 1b studies of aldoxorubicin to treat bone cancer sending the stock
price soaring 95 cents to $4.65.